Clinical Trials Browser

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT03094286 2024-06-24

Durvalumab in HIV-1 Patients With Solid Tumors

Phase 2 Completed

20 enrolled 36 charts

Tumor-Agnostic

Neoplasms

NCT04392505 2024-02-29

DART

Phase 2 Active not recruiting

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

1,550 enrolled

Tumor-Agnostic

Neoplasms

NCT02904954 2023-10-11

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

Phase 2 Completed

60 enrolled 12 charts

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03759496 2022-03-23

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Phase 2 Unknown

39 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasms

Clinical Trials

MINUTE

I-SPY

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

SAKK 06/17

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Durvalumab in HIV-1 Patients With Solid Tumors

DART

DRUP

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer